NCT05555732 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05555732
Title	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Acronym	TROPION-Lung07
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Daiichi Sankyo, Inc.
Indications	lung non-small cell carcinoma
Therapies	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.